- First patient dosed in Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy in
September 2026 - Nominated KER-206, a novel ligand trap designed to bind select TGF-ß ligands to regulate bone remodeling, from nonclinical pipeline for further investigation
- Cash runway expected into the second half of 2028
“We are excited to continue advancing our pipeline across both clinical and nonclinical development, building on our understanding of TGF-ß biology to develop potential new treatments for patients,” said
Recent Program Updates
- Rinvatercept for the treatment of Duchenne muscular dystrophy (“DMD”): In
September 2026 , Keros announced the first patient was dosed in the Phase 2 clinical trial of rinvatercept in patients with DMD. Keros expects to announce initial data from this trial in the first half of 2027. - KER-206: In
October 2026 , Keros presented a nonclinical poster on a research version of KER-206, or RKER-206, at theAmerican Society for Bone and Mineral Research 2026 Annual Meeting.
- KER-206 is a nonclinical asset designed to bind select ligands from the TGF-ß superfamily, including activin A, activin B, GDF8 and GDF11, which regulate bone remodeling through effects on differentiation and activity of bone-resorptive cells (osteoclasts) and bone-forming cells (osteoblasts). Through inhibition of these TGF-ß ligands, the Company believes that KER-206 has the potential to increase bone mass and improve skeletal integrity in disorders characterized by pathological bone loss.
Third Quarter 2026 Financial Results
Keros reported net income of
Research and development expenses were
General and administrative expenses were
Keros’ cash and cash equivalents as of
About
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, rinvatercept, is being developed for the treatment of DMD and for the treatment of amyotrophic lateral sclerosis. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis.
Cautionary Note Regarding Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “continue,” “expect,” “believe,” “will,” “may,” “potential,” or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: Keros’ expectations regarding its growth, strategy, progress and the advancement of its clinical and nonclinical pipeline; the development plans and potential therapeutic benefits of its product candidates; the design, objectives and timing of its clinical trials for rinvatercept; the potential of KER-206 to increase bone mass and improve skeletal integrity in disorders characterized by pathological bone loss; and Keros’ expected cash runway and ability to fund its operating expenses and capital expenditure requirements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Keros’ limited operating history and historical losses; Keros’ ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros’ dependence on the success of its product candidates, rinvatercept and elritercept; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros’ ability to obtain, maintain and protect its intellectual property; and Keros’ dependence on third parties in connection with manufacturing, clinical trials and nonclinical studies.
These and other risks are described more fully in Keros’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q, filed with the
Investor Contact:
jfrantz@kerostx.com
617-221-6042
Condensed Consolidated Statements of Operations (In thousands, except share and per share data) (Unaudited) | |||||||||||||||
| THREE MONTHS ENDED | NINE MONTHS ENDED | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| REVENUE: | |||||||||||||||
| Service and other revenue | $ | 9 | $ | 4,262 | $ | 376 | $ | 38,321 | |||||||
| License revenue | 40,000 | 10,000 | 40,000 | 205,355 | |||||||||||
| Total revenue | 40,009 | 14,262 | 40,376 | 243,676 | |||||||||||
| OPERATING EXPENSES: | |||||||||||||||
| Research and development | (20,491 | ) | (19,519 | ) | (58,919 | ) | (111,731 | ) | |||||||
| General and administrative | (6,700 | ) | (10,127 | ) | (25,453 | ) | (35,106 | ) | |||||||
| Total operating expenses | (27,191 | ) | (29,646 | ) | (84,372 | ) | (146,837 | ) | |||||||
| INCOME (LOSS) FROM OPERATIONS | 12,818 | (15,384 | ) | (43,996 | ) | 96,839 | |||||||||
| OTHER INCOME (EXPENSE), NET | |||||||||||||||
| Interest income, net | 55 | — | 55 | — | |||||||||||
| Dividend income | 2,220 | 6,933 | 6,842 | 20,845 | |||||||||||
| Other expense, net | (168 | ) | (253 | ) | (394 | ) | (812 | ) | |||||||
| Total other income, net | 2,107 | 6,680 | 6,503 | 20,033 | |||||||||||
| Income (loss) before income taxes | 14,925 | (8,704 | ) | (37,493 | ) | 116,872 | |||||||||
| Income tax (provision) benefit | (772 | ) | 1,424 | (772 | ) | (6,397 | ) | ||||||||
| Net income (loss) | $ | 14,153 | $ | (7,280 | ) | $ | (38,265 | ) | $ | 110,475 | |||||
| Net income (loss) attributable to common stockholders—basic and diluted | $ | 14,153 | $ | (7,280 | ) | $ | (38,265 | ) | $ | 110,475 | |||||
| Weighted-average shares of common stock outstanding — basic | 19,886,097 | 40,623,364 | 19,773,047 | 40,598,777 | |||||||||||
| Weighted-average shares of common stock outstanding — diluted | 20,341,140 | 40,623,364 | 19,773,047 | 41,202,371 | |||||||||||
| Net income (loss) per share of common stock — basic | $ | 0.71 | $ | (0.18 | ) | $ | (1.94 | ) | $ | 2.72 | |||||
| Net income (loss) per share of common stock — diluted | $ | 0.70 | $ | (0.18 | ) | $ | (1.94 | ) | $ | 2.68 | |||||
Condensed Consolidated Balance Sheets (In thousands, except share and per share data) (Unaudited) | |||||||
2026 | 2025 | ||||||
| ASSETS | |||||||
| CURRENT ASSETS: | |||||||
| Cash and cash equivalents | $ | 259,464 | $ | 287,415 | |||
| Accounts receivable | 20,000 | 3,567 | |||||
| Prepaid expenses and other current assets | 5,920 | 22,202 | |||||
| Current income tax receivable | 2,250 | 2,250 | |||||
| Total current assets | 287,634 | 315,434 | |||||
| Operating lease right-of-use assets | 14,887 | 16,841 | |||||
| Property and equipment, net | 3,390 | 4,297 | |||||
| Restricted cash | 1,449 | 1,449 | |||||
| Other long-term assets | 11 | — | |||||
| TOTAL ASSETS | $ | 307,371 | $ | 338,021 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| CURRENT LIABILITIES: | |||||||
| Accounts payable | $ | 3,787 | $ | 1,967 | |||
| Current portion of operating lease liabilities | 2,695 | 2,408 | |||||
| Accrued expenses and other current liabilities | 8,761 | 16,039 | |||||
| Current tax liability | 615 | — | |||||
| Total current liabilities | 15,858 | 20,414 | |||||
| Operating lease liabilities, net of current portion | 12,415 | 14,475 | |||||
| Total liabilities | 28,273 | 34,889 | |||||
| STOCKHOLDERS' EQUITY: | |||||||
| Preferred stock, par value of 30, 2026 and | — | — | |||||
| Series A junior participating preferred stock, par value of as of | — | — | |||||
| Common stock, par value of | 4 | 4 | |||||
| (386,211 | ) | (384,558 | ) | ||||
| Additional paid-in capital | 1,185,335 | 1,169,451 | |||||
| Accumulated deficit | (520,030 | ) | (481,765 | ) | |||
| Total stockholders' equity | 279,098 | 303,132 | |||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 307,371 | $ | 338,021 | |||
Source: 